Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Current cancer immunotherapy relies on adaptive immune checkpoints, with limited success in sustained patient responses.
• Tumor microenvironments feature myeloid cells inhibited by overexpressed immune checkpoint molecules, presenting new therapeutic targets.

Purpose of the Study:

• To review recent advancements in understanding CD24 and CD200 as immune checkpoint molecules in cancer.
• To explore the therapeutic potential of targeting CD24 and CD200 for cancer treatment.

Main Methods:

• Literature review of recent investigations on CD24, CD200, and their receptors (Siglec-10, CD200 receptor).
• Analysis of the role of these molecules in tumor immune evasion and myeloid cell inhibition.

Main Results:

• CD24 and CD200 are frequently overexpressed in various cancer types, contributing to immune evasion.
• These molecules engage Siglec-10 and CD200 receptor on myeloid cells, acting as critical signaling checkpoints.

Conclusions:

• CD24 and CD200 represent significant emergent immune checkpoints with substantial therapeutic potential.
• Targeting CD24 and CD200 offers a promising avenue for developing novel anticancer immunotherapies.